Coeptis Therapeutics Reports First Quarter 2025 Financial Results with $62,874 in Sales

Coeptis Therapeutics Holdings, Inc. reported its financial results for the first quarter of 2025, revealing total sales of $62,874, a significant increase from zero sales in the same period last year. The company recorded a gross profit of $17,718, with a cost of goods sold amounting to $45,156. However, the overall financial performance was marked by a net loss of $3,420,941, compared to a net loss of $3,001,388 in the first quarter of 2024. This resulted in a loss per share of $1.11, a notable increase from the loss per share of $0.08 reported in the prior year.

Operating expenses for the quarter rose to $4,074,702, up from $2,922,383 in the same quarter of 2024. The increase was primarily driven by higher professional services expenses, which were largely related to equity transactions, and a significant rise in stock-based compensation expenses, which totaled $597,731 compared to $96,889 in the previous year. Research and development expenses decreased to $86,659 from $777,069, reflecting a strategic shift in focus following the termination of a shared services agreement with Deverra Therapeutics.

In terms of strategic developments, Coeptis has made significant strides in its biotechnology segment, particularly with the licensing of the GEAR™ Cell Therapy Platform from Vy-Gen-Bio, Inc. This agreement allows Coeptis to develop and commercialize innovative therapies targeting hematologic malignancies and other cancers. The company also completed a Series A preferred stock offering, raising a total of $10 million, which is expected to enhance its financial position and support ongoing operations.

Operationally, Coeptis reported an increase in cash and cash equivalents, which rose to $4,268,368 as of March 31, 2025, compared to $1,029,244 at the end of the previous year. The company has also recorded customer deposits amounting to $1,187,126, indicating a growing interest in its services. However, the company continues to face challenges in achieving profitability, with an accumulated deficit of $101,654,614 as of the end of the quarter.

Looking ahead, Coeptis remains focused on advancing its product development initiatives and exploring additional strategic partnerships. Management anticipates that the ability to raise capital through equity transactions will improve liquidity and facilitate the execution of its operational strategy. However, the company has cautioned that it does not expect to generate significant revenue for at least the next two years as it continues to develop its pipeline of therapies.